Table 1.
Sociodemographic and clinical characteristics of study participants.
Fig 1.
A: Genotype distribution of hr- and lr-HPV among women with HPV infection (N = 83).
Frequency of HPV genotypes for all women at baseline. The salmon bars indicate hr- HPV genotypes, the blue bars indicate lr-HPV genotypes and the dotted bars indicate strains included in vaccines. B: Type-specific HPV genotype frequency at baseline (N = 83). The blue bars indicate lr-HPV genotypes, salmon bars indicate hr-HPV genotypes, and solid gray bars indicate, any HPV genotype, number of HPV genotypes, single and multiple HPV genotypes, and vaccine type strains. Hr-HPV is defined as infection with any of the following HPV genotypes: HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, or -68. Lr-HPV is defined as infection with any of the following HPV genotypes: HPV-6, -11, -26, -40, -42, -53, -54, -55, -61, -62, -64, -67, -69, -70, -71, -72, -73, -81, -82 subtype (IS39), -83, -84, and -89 (CP6108). Cervarix® HPV vaccine is defined as infection with HPV types-16 and -18. Gardasil®4 HPV vaccine is defined as infection with any of the following HPV types: HPV-6, -11, -16, or -18. Gardasil®9 HPV vaccine is defined as infection with HPV-6, -11, -16, -18, -31, -33, -45, -52, or -58.
Table 2.
Co-detection of HPV and other STIs and/or BV (N = 83).
Table 3.
Associations between HPV, STIs, and/or BV.
Table 4.
Association between HPV, STI, and/BV and biomarkers of epithelial barrier integrity.